People often ask how Charco is working, and what we do day to day. Well, we have now decided to share our behind-the-scenes workings with you! In what is the first in a series of articles looking at what goes on behind the scenes at Charco, we discuss how we have developed our CUE1 app.
We are incredibly excited to announce that we have now completed the report for our second round of user testing.
Parkinson’s disease is named after the first person to recognise it as a distinct illness – Dr. James Parkinson (1755-1824). An interesting figure, he was not just a good doctor but a keen scientist, political reformer and philanthropist.
Professor Jean-Martin Charcot (1825-1893) is generally regarded as one of the greatest early neurologists
; a pioneer whose diagnostic work has continued to influence medicine in the modern age. It’s hard to understate the influence Professor Charcot had on the field of neurology.
The Charco Neurotech team are developing the CUE1
device with, and for, people with Parkinson’s. We are therefore grateful to have spoken with another medical technology company founder, Bruce Hellman, co-founder and CEO of uMotif
,to hear what inspired him
Dr Sweta Adatia is a highly qualified and experienced Clinical Neurologist who is currently studying for an MBA at Cambridge Business School. She has experience studying and practicing